An International Multicentre, Open-Label First in Human Phase I/II Study to Evaluate the Safety, Tolerability, Biodistribution and Antitumour Activity of 177Lu-3BP-227 for the Treatment of Subjects With Solid Tumours Expressing Neurotensin Receptor 1
Phase of Trial: Phase I/II
Latest Information Update: 24 Dec 2019
Price : $35 *
At a glance
- Drugs IPN 01087 (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Ewing's sarcoma; Gastric cancer; Gastrointestinal stromal tumours; Head and neck cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Ipsen
- 29 Nov 2018 Planned number of patients changed from 300 to 320.
- 29 Nov 2018 Planned End Date changed from 22 Nov 2021 to 28 Mar 2022.
- 29 Nov 2018 Planned primary completion date changed from 27 Sep 2021 to 7 Apr 2020.